# Arbor Pharmaceuticals

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/arbor-pharmaceuticals

- Industry: Pharmaceuticals
- Headquarters: Atlanta, US
- Website: www.arborpharma.com
- Total disclosed funding: $17M
- Latest round: Series B (Nov 5, 2010)
- Investors on record: 3

## About

Arbor Pharmaceuticals, LLC is a US-based specialty pharmaceutical company focused on developing and commercializing innovative medications for underserved patient populations.Founded in 2006 and headquartered in Atlanta, US, Arbor Pharmaceuticals develops specialty medications with a commitment to enhancing patient care. The company was acquired in August 2021 by Azurity Pharmaceuticals, aligning with a strategy to expand the range of patient-centric products. Ed Schutter serves as the CEO of Arbor Pharmaceuticals. The company has engaged in 5 deals overall, with the most recent funding round being a VENTURE DEBT round amounting to USD 17.30 mn, bringing the total amount raised to USD 17.415 mn.Arbor Pharmaceuticals offers a diverse portfolio of over 50 medications across 10 dosage forms and key therapeutic areas, which include Allergy, Cardiovascular, Central Nervous System, Endocrinology, Gastrointestinal, Hematology, Immunology, Oncology, and Respiratory health. Among its notable products are BRYNOVIN™ (sitagliptin), used for type 2 diabetes management, and XIFYRM™ (meloxicam injection), a non-steroidal anti-inflammatory drug for moderate-to-severe pain. These products are marketed in over 50 countries, targeting healthcare providers and patients requiring specialty therapeutic solutions.Arbor Pharmaceuticals generates revenue primarily through direct sales of its branded products to healthcare providers, hospitals, and specialty pharmacies. Utilizing a B2B approach, the company partners with distributors and healthcare networks to enhance product accessibility. Sales are structured through pricing agreements that consider the therapeutic benefits and market demand of its offerings, including key products like BRYNOVIN™ and XIFYRM™, while also focusing on patient support and adherence initiatives to improve treatment outcomes.Following the acquisition by Azurity Pharmaceuticals in August 2021, Arbor Pharmaceuticals aims to bolster its product line and market reach. The company plans to introduce new products designed to address unmet medical needs, although specific details on release dates remain undisclosed. Expanding into additional markets is also a priority, with targeted regions yet to be specified. The recent VENTURE DEBT funding of USD 17.30 mn will support these initiatives, aligning with the overarching vision of developing high-value products that cater to patient requirements.

## Funding rounds

- Series B, Nov 5, 2010, $17M — JW Asset Management, Signet Healthcare Partners, ARCH Healthcare Fund

## Investors

- JW Asset Management (https://capitalatlas.ai/funds/jw-asset-management) — Series B
- Signet Healthcare Partners (https://capitalatlas.ai/funds/signet-healthcare-partners) — Series B
- ARCH Healthcare Fund — Series B